Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2014.421 http://scihub22266oqcxt.onion/10.1038/bjc.2014.421 C4453852!4453852 !25093491     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25093491 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Cancer 2014 ; 111 (6 ): 1168-79 Nephropedia Template TP {{tp|p=25093491 |t=2014. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells |pdf=|usr=}}{{25093491 }} gab.com Text Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25093491 #FOAvip BACKGROUND: Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in the maintenance and progression of different human cancers. Therefore, inhibition of the Hh pathway represents a valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is a Smoothened (Smo) antagonist that induces dose-related inhibition of Hh and Smo-dependent tumour growth. METHODS: We assayed the effects of NVP-LDE225 alone or in combination with everolimus or sunitinib on the growth and invasion of human RCC models both in vitro and in vivo. To this aim, we used a panel of human RCC models, comprising cells with acquired resistance to sunitinib - a multiple tyrosine kinase inhibitor approved as a first-line treatment for RCC. RESULTS: NVP-LDE225 cooperated with either everolimus or sunitinib to inhibit proliferation, migration, and invasion of RCC cells even in sunitinib-resistant (SuR) cells. Some major transducers involved in tumour cell motility, including paxillin, were also efficiently inhibited by the combination therapy, as demonstrated by western blot and confocal microscopy assays. Moreover, these combined treatments inhibited tumour growth and increased animal survival in nude mice xenografted with SuR RCC cells. Finally, lung micrometastasis formation was reduced when mice were treated with NVP-LDE225 plus everolimus or sunitinib, as evidenced by artificial metastatic assays. CONCLUSIONS: Hedgehog inhibition by NVP-LDE225 plus sunitinib or everolimus bolsters antitumour activity by interfering with tumour growth and metastatic spread, even in SuR cells. Thus, this new evidence puts forward a new promising therapeutic approach for RCC patients. Twit Text FOAVip Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25093491 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25093491 #FOAvip English Wikipedia <ref>{{Cite pmid|25093491 }}</ref> Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells #MMPMID25093491 D'Amato C ; Rosa R ; Marciano R ; D'Amato V ; Formisano L ; Nappi L ; Raimondo L ; Di Mauro C ; Servetto A ; Fulciniti F ; Cipolletta A ; Bianco C ; Ciardiello F ; Veneziani BM ; De Placido S ; Bianco R Br J Cancer 2014[Sep]; 111 (6 ): 1168-79 PMID25093491 show ga BACKGROUND: Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in the maintenance and progression of different human cancers. Therefore, inhibition of the Hh pathway represents a valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is a Smoothened (Smo) antagonist that induces dose-related inhibition of Hh and Smo-dependent tumour growth. METHODS: We assayed the effects of NVP-LDE225 alone or in combination with everolimus or sunitinib on the growth and invasion of human RCC models both in vitro and in vivo. To this aim, we used a panel of human RCC models, comprising cells with acquired resistance to sunitinib - a multiple tyrosine kinase inhibitor approved as a first-line treatment for RCC. RESULTS: NVP-LDE225 cooperated with either everolimus or sunitinib to inhibit proliferation, migration, and invasion of RCC cells even in sunitinib-resistant (SuR) cells. Some major transducers involved in tumour cell motility, including paxillin, were also efficiently inhibited by the combination therapy, as demonstrated by western blot and confocal microscopy assays. Moreover, these combined treatments inhibited tumour growth and increased animal survival in nude mice xenografted with SuR RCC cells. Finally, lung micrometastasis formation was reduced when mice were treated with NVP-LDE225 plus everolimus or sunitinib, as evidenced by artificial metastatic assays. CONCLUSIONS: Hedgehog inhibition by NVP-LDE225 plus sunitinib or everolimus bolsters antitumour activity by interfering with tumour growth and metastatic spread, even in SuR cells. Thus, this new evidence puts forward a new promising therapeutic approach for RCC patients. |Actin Cytoskeleton/ultrastructure [MESH] |Actins/ultrastructure [MESH] |Animals [MESH] |Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*pharmacology [MESH] |Biphenyl Compounds/administration & dosage [MESH] |Carcinoma, Renal Cell/*drug therapy/secondary [MESH] |Cell Line, Tumor [MESH] |Cell Movement/drug effects [MESH] |Cell Proliferation/drug effects [MESH] |Drug Synergism [MESH] |Everolimus [MESH] |Hedgehog Proteins/*metabolism [MESH] |Humans [MESH] |Indoles/administration & dosage [MESH] |Inhibitory Concentration 50 [MESH] |Kidney Neoplasms/*drug therapy/pathology [MESH] |Kruppel-Like Transcription Factors/metabolism [MESH] |Lung Neoplasms/*secondary [MESH] |Mice [MESH] |Mice, Inbred BALB C [MESH] |Mice, Nude [MESH] |Mitogen-Activated Protein Kinases/metabolism [MESH] |Neoplasm Micrometastasis/drug therapy [MESH] |Nuclear Proteins/metabolism [MESH] |Paxillin/metabolism/ultrastructure [MESH] |Proto-Oncogene Proteins c-akt/metabolism [MESH] |Pyridines/administration & dosage [MESH] |Pyrroles/administration & dosage [MESH] |Receptors, G-Protein-Coupled/antagonists & inhibitors/metabolism [MESH] |Ribosomal Protein S6 Kinases, 70-kDa/metabolism [MESH] |Signal Transduction/*drug effects [MESH] |Sirolimus/administration & dosage/analogs & derivatives [MESH] |Smoothened Receptor [MESH] |Sunitinib [MESH] |Transcription Factors/metabolism [MESH] |Tumor Burden/*drug effects [MESH] |Xenograft Model Antitumor Assays [MESH] |Zinc Finger Protein GLI1 [MESH]Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interfer(epmc).pdf DeepDyve Pubget Overpricing